Single-arm, multi-institution for Refractory Multiple Myeloma

Phase-Based Progress Estimates
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, United States
Refractory Multiple Myeloma+2 More
Belantamab mafodotin - Drug
All Sexes
What conditions do you have?

Study Summary

This is a single arm, multi-institution (1) Hackensack Meridian Health at Hackensack, New Jersey (NJ) (2) Jersey Shore Medical Center, Neptune, NJ and (3) Georgetown/Lombardi Cancer Center) phase II study of the combination of pembrolizumab, belantamab, and dexamethasone in patients with triple class refractory multiple myeloma.

Eligible Conditions

  • Refractory Multiple Myeloma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Refractory Multiple Myeloma

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 2 years

2 years
Overall Response Rate (ORR)
Overall Survival (OS)
Progression-Free Survival (PFS)
Time to next treatment
Tolerability and Safety

Trial Safety

Safety Progress

1 of 3

Other trials for Refractory Multiple Myeloma

Trial Design

1 Treatment Group

Single-arm, multi-institution
1 of 1
Experimental Treatment

64 Total Participants · 1 Treatment Group

Primary Treatment: Single-arm, multi-institution · No Placebo Group · Phase 1 & 2

Single-arm, multi-institutionExperimental Group · 3 Interventions: Belantamab mafodotin, Dexamethasone, Pembrolizumab · Intervention Types: Drug, Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Belantamab mafodotin
Completed Phase 1
Completed Phase 4
Completed Phase 3

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years
Closest Location: Lombardi Comprehensive Cancer Center, Georgetown University · Washington, United States
Photo of washington  1Photo of washington  2Photo of washington  3
2007First Recorded Clinical Trial
1 TrialsResearching Refractory Multiple Myeloma
2 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You cannot take an immunomodulating agent during the study.
You have a M-protein level of 0.5 g/dL (0.
You have a serum free light chain level greater than 100 mg/L.
You are not eligible for CAR T-cell therapy.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.